Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1842223

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1842223

Ovarian Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), By Diagnosis (Imaging, Blood Test, Biopsy), By End-use, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Ovarian Cancer Diagnostics Market Summary

The global ovarian cancer diagnostics market size was estimated at USD 1.74 billion in 2024 and is projected to reach USD 3.11 billion by 2033, growing at a CAGR of 6.73% from 2025 to 2033. The ovarian cancer diagnostics market is advancing rapidly, driven by biomarker discovery, federal funding, and new technologies.

In 2025, the U.S. will see nearly 21,000 new cases and over 12,000 deaths, underscoring the need for earlier detection. Breakthroughs include PPP2R1A mutations as predictive biomarkers in ovarian clear cell carcinoma and AOA Dx's multi-omic, AI-powered blood test, which achieved >90% accuracy in symptomatic women, outperforming traditional biomarkers. Federal support is strong, with the DoD allocating $650M in FY25 to the Ovarian Cancer Research Program, funding precision medicine, prevention, and survivorship studies. Despite progress, testing disparities persist, particularly in older and underserved women. Overall, the market is shifting toward precision, multi-omic, and patient-centric diagnostics with significant growth potential.

The ovarian cancer diagnostics market is significantly transforming, shaped by epidemiological need, biomarker discovery, technological innovation, and shifting clinical strategies. In 2025, an estimated 20,890 new cases of ovarian cancer will be diagnosed in the U.S., with 12,730 deaths (American Cancer Society). Despite being the 11th most common cancer among women, ovarian cancer remains the fifth leading cause of cancer-related death and the deadliest gynecologic malignancy. As of 2022, approximately 243,572 women in the U.S. were living with a prior ovarian cancer diagnosis (SEER), reflecting the growing patient base that depends on early and accurate diagnostics. Significantly, mortality rates are modestly declining but lag behind improvements seen in other cancers, highlighting the urgency for better detection and stratification tools.

The market is increasingly shaped by biomarker-driven innovation. A landmark discovery in July 2025 at MD Anderson Cancer Center identified PPP2R1A mutations as a predictive biomarker for improved survival in ovarian clear cell carcinoma (OCCC) treated with immunotherapy, with median overall survival extending to 66.9 months versus 9.2 months in non-mutant patients. This breakthrough validates immunogenomic diagnostics and highlights the role of genetic testing in patient stratification, fueling demand for next-generation molecular diagnostics. Parallel efforts focus on the PP2A pathway, with early-phase trials exploring therapeutic targeting in OCCC and other tumor types, demonstrating how diagnostics and therapeutics converge in a precision oncology framework.

In parallel, large-scale funding initiatives are reinforcing this momentum. In April 2025, the U.S. Department of Defense (DoD) announced $650 million in appropriations for its Congressionally Directed Medical Research Programs (CDMRP), with a dedicated portion for the Ovarian Cancer Research Program (OCRP). The FY25 OCRP will support high-impact research on early detection, prevention, survivorship, and precision medicine, offering major grants such as the Investigator-Initiated Research Award (up to $1.05M), the Clinical Trial Academy - Early Career Investigator Award (up to $1.4M), and Pilot Awards (up to $350K). These investments signal strong federal backing to accelerate diagnostic innovation and improve clinical outcomes.

Despite advances, testing gaps remain a significant market driver. In March 2025, the Ovarian Cancer Research Alliance (OCRA) and Komodo Health reported that nearly half of women with ovarian cancer are not receiving genetic testing, despite universal guidelines. Disparities are most evident among women over 65 and those on public insurance, where testing rates fall below 40%. Since genetic testing underpins therapy selection particularly for BRCA mutation-positive patients eligible for PARP inhibitors addressing these gaps is central to improving outcomes. As a result, organizations like OCRA are expanding patient-support tools, such as the "Find a Doctor" platform (launched April 2024), which connects patients to more than 2,000 gynecologic oncology specialists and integrates trial-finder functionality, increasing awareness and adoption of diagnostics.

The market also benefits from strategic realignment in preventive strategies. Following evidence from large-scale UK trials showing the limited impact of symptom-based detection on mortality, OCRA and the Society of Gynecologic Oncology (SGO) began advocating for universal genetic testing and opportunistic salpingectomy (fallopian tube removal during pelvic surgery) in 2023. This shift reflects a growing reliance on risk-based and genetic diagnostics rather than conventional screening, driving greater uptake of molecular and genomic tests.

Technological breakthroughs are also redefining early detection. In August 2025, AOA Dx published peer-reviewed results in Cancer Research Communications showing that its multi-omic, AI-powered blood test achieved strong accuracy in symptomatic women, with an AUC of 93% for all stages and 91% for early-stage ovarian cancer in training cohorts, and 92% and 88% respectively, in independent real-world cohorts. The platform outperformed traditional biomarkers by combining lipid, ganglioside, and protein biomarkers with machine learning, offering a scalable, non-invasive solution that could transform early-stage detection, where survival benefits are most significant.

Furthermore, initiatives such as OCRA's international data commons and the first ovarian ad endometrial cancer registry (2023) create the infrastructure for large-scale real-world evidence generation. By consolidating patient-level genomic and clinical data, these efforts aim to accelerate biomarker discovery, improve predictive diagnostics, and inform payor adoption an increasingly important growth lever for the diagnostics industry.

Overall, the ovarian cancer diagnostics market moves rapidly from traditional pathology and symptom awareness toward a genomics-led, precision-driven, patient-centered model. Growth is fueled by a convergence of factors: rising disease prevalence, breakthrough biomarkers such as PPP2R1A, demand for equitable access to genetic testing, integration of digital patient navigation tools, robust federal research funding, and international collaboration in data-driven research. While challenges around testing disparities, cost barriers, and lack of validated early screening tools persist, the sector is evolving into a high-value segment of the broader next-generation cancer diagnostics market. Its trajectory is increasingly defined by companion diagnostics, liquid biopsy innovations, and immunogenomic testing, which are expected to unlock significant commercial and clinical opportunities over the next decade.

Global Ovarian Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ovarian cancer diagnostics market report based on cancer, diagnosis, end-use, and region:

  • Cancer Outlook (Revenue, USD Million, 2021 - 2033)
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Others
  • Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
    • Ultrasound
    • CT Scan
    • MRI Scan
    • PET Scan
    • Others
  • Blood Test
    • CA125
    • HER2
    • BRCA
    • CEA
    • ER & PR
    • KRAS Mutation
    • Others
  • Biopsy
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • UAE
    • South Arabia
    • South Africa
    • Kuwait
Show more
Product Code: GVR-3-68038-421-5

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Ovarian Cancer Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Ovarian Cancer Diagnostics Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Ovarian Cancer Diagnostics Market: Cancer Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Epithelial Tumor
    • 4.3.1. Epithelial Tumor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Germ Cell Tumor
    • 4.4.1. Germ Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Stromal Cell Tumor
    • 4.5.1. Stromal Cell Tumor Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ovarian Cancer Diagnostics Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Ovarian Cancer Diagnostics Market: Diagnosis Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. Imaging
    • 5.3.1. Imaging Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Blood Test
    • 5.4.1. Blood Test Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biopsy
    • 5.5.1. Biopsy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ovarian Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Ovarian Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Hospital Laboratories
    • 6.3.1. Hospital Laboratories Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Cancer Diagnostic Centers
    • 6.4.1. Cancer Diagnostic Centers Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Research Institutes
    • 6.5.1. Research Institutes Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ovarian Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Ovarian Cancer Diagnostics Market Share, By Region, 2024 & 2033 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. South Africa
      • 7.6.3.1. South Africa Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Ovarian Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GlaxoSmithKline Plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. AstraZeneca Plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Siemens Healthcare GmbH
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Abbott
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Thermo Fisher Scientific
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Bio-Rad Laboratories, Inc
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Quest Diagnostics Incorporated
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Illumina, Inc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
Show more
Product Code: GVR-3-68038-421-5

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Ovarian Cancer Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 5 Global Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 6 Global Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 7 Global Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 9 North America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 10 North America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 11 North America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 13 U.S. Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 14 U.S. Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15 Canada Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 16 Canada Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 17 Canada Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18 Mexico Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 19 Mexico Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 20 Mexico Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Europe Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 22 Europe Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 23 Europe Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 24 Europe Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 UK Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 26 UK Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 27 UK Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28 Germany Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 29 Germany Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 30 Germany Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 31 France Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 32 France Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 33 France Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Spain Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 35 Spain Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 36 Spain Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37 Italy Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 38 Italy Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 39 Italy Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 40 Denmark Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 41 Denmark Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 42 Denmark Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43 Sweden Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 44 Sweden Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 45 Sweden Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Norway Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 47 Norway Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 48 Norway Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 50 Asia Pacific Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 54 Japan Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 55 Japan Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56 China Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 57 China Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 58 China Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59 Australia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 60 Australia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 61 Australia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Thailand Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 63 Thailand Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 64 Thailand Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65 India Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 66 India Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 67 India Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 68 South Korea Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 69 South Korea Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 70 South Korea Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 Latin America Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 72 Latin America Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 73 Latin America Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 74 Latin America Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 Brazil Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 76 Brazil Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 77 Brazil Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 78 Argentina Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 79 Argentina Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 80 Argentina Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 81 MEA Ovarian Cancer Diagnostics Market, By Country, 2021- 2033 (USD Million)
  • Table 82 MEA Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 83 MEA Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 84 MEA Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 85 South Africa Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 86 South Africa Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 87 South Africa Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 UAE Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 92 UAE Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 93 UAE Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Ovarian Cancer Diagnostics Market, By Diagnosis, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Ovarian Cancer Diagnostics Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Ovarian Cancer Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ovarian cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Ovarian cancer diagnostics market snapshot
  • Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD Million)
  • Fig. 11 Market Dynamics
  • Fig. 12 Ovarian cancer diagnostics market driver impact
  • Fig. 13 Ovarian cancer diagnostics market restraint impact
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ovarian cancer diagnostics market: Diagnosis outlook and key takeaways
  • Fig. 16 Imaging market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Blood test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Biopsy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Ovarian cancer diagnostics market : Cancer outlook and key takeaways
  • Fig. 21 Ovarian cancer diagnostics market: Cancer movement analysis
  • Fig. 22 Epithelial tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Germ cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Stromal cell tumor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Ovarian cancer diagnostics market : End Use outlook and key takeaways
  • Fig. 27 Ovarian cancer diagnostics market: End Use movement analysis
  • Fig. 28 Hospital laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Cancer diagnostic centers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Research institutes market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Ovarian Cancer Diagnostics Market: Regional outlook and key takeaways
  • Fig. 33 Ovarian Cancer Diagnostics Market: Regional movement analysis
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico
  • Fig. 41 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Italy
  • Fig. 53 Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Japan
  • Fig. 63 Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 China
  • Fig. 65 China. market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Thailad
  • Fig. 69 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Australia
  • Fig. 71 Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea
  • Fig. 73 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina
  • Fig. 79 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 80 MEA
  • Fig. 81 MEA market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa
  • Fig. 83 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia
  • Fig. 85 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 UAE
  • Fig. 87 UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait
  • Fig. 89 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 Ansoff Matrix
  • Fig. 91 Strategy mapping
  • Fig. 92 Company market share analysis, 2022
  • Fig. 93 Heat Map Analysis
  • Fig. 94 Market differentiators
  • Fig. 95 Heat Map Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!